Home
Learn More
Features & Pricing
Success Stories
Contact Us
Search Archives
PRWeb Direct
Submit Release
September 8, 2008
 
Industry Categories  
News by Country  
News by MSA  
Todays News  
Browse by Day  
PR Trackbacks™  
Featured Videos  
ViewNews™  
eBook Digests  
RSS  
PRWeb, a leader in online news and press release distribution, has been used by more than 40,000 organizations of all sizes to increase the visibility of their news, improve their search engine rankings and drive traffic to their Web site.
 
Close Move
All Press Releases for February 15, 2006 Subscribe to this News Feed      
 

How Competition Can Compromise the Cause for Kidney Cancer Patients

Guest editorial in Kidney Cancer Journal co-authored by leading oncologist calls for unity among cancer advocates.

(PRWEB) February 15, 2006 -- The current issue of Kidney Cancer Journal features a guest editorial co-authored by Janice P. Dutcher, MD, Associate Director for Clinical Affairs, Our Lady of Mercy Comprehensive Cancer Center, Bronx, New York, and Professor of Medicine New York Medical College, Valhalla, New York.

Dr. Dutcher, one of the nation's leading kidney cancer researchers, along with William P. Bro, CEO of the Chicago-based Kidney Cancer Association (KCA), call for unity among cancer advocates. The editorial explains that some disease advocates have begun lobbying the federal government to earmark funds specifically for kidney cancer. However, this approach is not only contrary to the KCA’s position, it is also fundamentally at odds with the congressional directive for NIH funding, as stated in the Appropriations Committee’s report. Dutcher and Bro argue that broad-based medical funding is better for everyone.

Research in one cancer area often leads to discoveries in another.
“We must remember that cancer research is not performed in a vacuum,” says KCA chairperson Paula Bowen, of New York. “Research in one cancer area often leads to discoveries in another.”

According to the editorial, a good example of this principle in action is the drug gemcitabine. First approved by the FDA for treatment of pancreatic cancer, it has since shown promise in reducing the size of renal cell tumors. By forming a unified front and working toward common goals, kidney cancer advocates can effect significant contributions in the fight for a cure that may ultimately benefit the entire cancer patient population.

Kidney Cancer Journal is available online at www.kidneycancerjournal.com. The website includes an archive of past issues.

The Kidney Cancer Association is the only global organization serving patients with renal cancers. It reaches more than 70-thousand constituents in 102 nations. Its mission is the eradication of death and suffering from kidney cancer.

# # #

See the original story at: http://www.prweb.com/releases/2006/02/prweb346138.htm

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/WmV0YS1TaW5nLVRoaXItU3F1YS1IYWxmLVplcm8=

Technorati Tags

Bookmark -  Del.icio.us | Digg | Furl It | Spurl | RawSugar | Simpy | Shadows | Blink It | My Web


Other Releases by this Member
OPTIONS
Printer Friendly Version
Download PDF Version
Download Reader Version
BlogThis
ShareIt

Share The News

Submit this press release easily to any of these major bookmarking and social media sites.

CONTACT INFORMATION
Celeste Kelley
KIDNEY CANCER ASSOCIATION
847-332-1051
Email us Here
ATTACHED FILES

Kidney Cancer Journal
Winter 2005-2006 issue of Kidney Cancer Journal (PDF)

ABOUT PRESS RELEASES
If you have any questions regarding information in these press releases please contact the company listed in the press release. Please do not contact PRWeb. We will be unable to assist you with your inquiry. PRWeb disclaims any content contained in these releases. Our complete disclaimer appears here.
 
Disclaimer: If you have any questions regarding information in these press releases please contact the company listed in the press release.
Please do not contact PRWeb®. We will be unable to assist you with your inquiry.
PRWeb® disclaims any content contained in these releases. Our complete disclaimer appears here.

© Copyright 1997-2008, Vocus PRW Holdings, LLC.
Vocus, PRWeb and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.

Terms of Service | Privacy Policy | Copyright